Switch theme
Sign up to access all valuation multiples
Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options. The company's pipeline includes products like COROST for Colorectal Cancer, PANTAX for Pancreatic Cancer, 101 for other cancer indiction, 201 for Solid Tumors.
2017
4
Last FY Revenue n/a
Last FY EBITDA -$4.2M
-$1.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Scandion Oncology achieved revenue of n/a and an EBITDA of -$4.2M.
Scandion Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scandion Oncology valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$4.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$4.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$3.8M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Scandion Oncology's stock price is SEK 0 (or $0).
Scandion Oncology has current market cap of SEK 4.1M (or $0.4M), and EV of -SEK 14.3M (or -$1.5M).
See Scandion Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.5M | $0.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Scandion Oncology has market cap of $0.4M and EV of -$1.5M.
Scandion Oncology's trades at n/a EV/Revenue multiple, and 0.4x EV/EBITDA.
Equity research analysts estimate Scandion Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scandion Oncology's P/E ratio is not available.
See valuation multiples for Scandion Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $0.4M | XXX | $0.4M | XXX | XXX | XXX |
| EV (current) | -$1.5M | XXX | -$1.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialScandion Oncology's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Scandion Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scandion Oncology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Scandion Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scandion Oncology acquired XXX companies to date.
Last acquisition by Scandion Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Scandion Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Scandion Oncology founded? | Scandion Oncology was founded in 2017. |
| Where is Scandion Oncology headquartered? | Scandion Oncology is headquartered in Sweden. |
| How many employees does Scandion Oncology have? | As of today, Scandion Oncology has 4 employees. |
| Is Scandion Oncology publicy listed? | Yes, Scandion Oncology is a public company listed on STO. |
| What is the stock symbol of Scandion Oncology? | Scandion Oncology trades under SCOL ticker. |
| When did Scandion Oncology go public? | Scandion Oncology went public in 2018. |
| Who are competitors of Scandion Oncology? | Similar companies to Scandion Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Scandion Oncology? | Scandion Oncology's current market cap is $0.4M |
| Is Scandion Oncology profitable? | Yes, Scandion Oncology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
